Browse the corpus

Bethanechol is an FDA-approved medication used to manage postoperative and postpartum urinary retention, as well as overflow incontinence due to neurogenic bladder atony, and belongs to the parasympathomimetic drug class. This activity focuses on the clinical applications of bethanechol in managing nonobstructive urinary retention-related disorders. The indications, administration modalities, and contraindications will be covered. The program equips participants with essential knowledge to optimize patient outcomes by emphasizing the drug's mechanism of action, adverse event profile, monitoring strategies, and clinical toxicology considerations. Furthermore, this activity explores critical aspects such as drug interactions and pharmacokinetics, enhancing healthcare professionals' proficiency in tailoring therapeutic approaches for patients with conditions associated with nonobstructive urinary retention. Objectives: Identify the mechanism of action of bethanechol. Assess the adverse drug reactions of bethanechol. Determine the appropriate monitoring of bethanechol. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from bethanechol therapy in nonobstructive urinary retention. Access free multiple choice questions on this topic.

Atropine sulfate competes with bethanechol at the muscarinic receptor junction, competitively blocking its binding at the postganglionic arch receptors and preventing parasympathetic cholinergic activation.[4][25] A 0.6 mg dosage of atropine is recommended for adults and is repeatable every 2 hours as needed, depending on therapeutic responses. Dosages that range from 0.01 to 0.4 mg/kg can be administered in the pediatric population (infant/children) and should be repeated every 2 hours as needed, depending on therapeutic responses. The subcutaneous route via injection is also an option. An emergency indicates the use of the intravenous administration route. This diagnosis of overdose and toxicity is based on clinical manifestations, as there are no definite lab examinations or radiographic imaging that will affirm the determination. The excessive parasympathetic action at M2 and M3 muscarinic receptors in the heart, GI tract, vasculature, and bronchial muscles generate an increased response resulting in bronchorrhea, salivation, lacrimation, diaphoresis, bronchoconstriction, chest tightness, decreased heart rate, decreased blood pressure, vomiting, increased gastrointestinal motility, abdominal tightness, diarrhea, and cramps. The disproportionate effects of muscarinic receptors in the eyes cause miosis and blurring vision.[15][17][26]

Bethanechol is a direct-acting parasympathomimetic agent that is FDA-approved for the treatment of postoperative urinary retention, postpartum urinary retention, and overflow incontinence caused by neurogenic atony of the bladder. Patients with urologic conditions require critical care from an interprofessional team of healthcare professionals. Pharmacologic management can lead to a better quality of life for patients. These healthcare professionals include family or primary care clinicians, urologists, gynecologists, nurses, and pharmacists. Primary care clinicians and specialists must be well-informed regarding the latest information for the appropriate dosage and indications of bethanechol. Prescribing clinicians should determine the minimum effective dosage via 5 to 10 mg repeated at hourly intervals until the desired therapeutic result is achieved. The primary care physician should routinely monitor patients taking this medication for therapeutic efficacy, as dosing modifications may be necessary. The prescriber should also be aware of any underlying contraindications, such as epilepsy, peptic ulcer disease, and COPD, before administration, as these conditions can exacerbate upon using the parasympathomimetic agent like bethanechol.[21] Patients should fully understand the multisystemic adverse events that may occur with bethanechol use. In the event of toxicity and overdose-causing systemic effects, atropine should be administered at a dose of 0.6 mg and repeated every 2 hours as needed until the effects subside. Counseling and careful monitoring are necessary during pregnancy, as clinical studies during its use in pregnancy are limited, and bethanechol is FDA pregnancy category C. This is where the nursing staff and pharmacists can contribute to therapy, with patient counseling on dosing and possible adverse events and helping to monitor therapeutic progress. Interprofessional teamwork and communication are crucial to building patient rapport and developing a therapeutic alliance so the patients comply with therapy competently. Continued teamwork between healthcare professionals will improve patient outcomes and quality of life while mitigating potential adverse drug reactions.